Q3-2021 FINANCIAL PERFORMANCE
Transcript of Q3-2021 FINANCIAL PERFORMANCE
![Page 1: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/1.jpg)
![Page 2: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/2.jpg)
Q3-2021 FINANCIAL PERFORMANCE
![Page 3: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/3.jpg)
หน่วย : ลา้นบาทไตรมาส 3/64
(ก.ค.-ก.ย.64)
ไตรมาส 3/63
(ก.ค.-ก.ย.63)เปลี่ยนแปลง+/(-)
9 เดือน ปี 64
(ม.ค.-ก.ย. 64)
9 เดือน ปี 63
(ม.ค.-ก.ย. 63)เปลี่ยนแปลง
รายไดร้วม 244.39 110.58 121.01% 623.54 310.78 100.64%
รายไดจ้ากการขาย 240.38 108.97 120.60% 615.18 306.75 100.55%
กาํไรขั้นตน้ 95.90 65.46 46% 279.10 187.36 49%
EBITDA 36.52 24.55 49% 104.29 66.66 56%
กาํไรสุทธิของกลุ่มบริษทัฯ 25.71 18.46 39% 69.15 49.25 40%
อตัรากาํไรขั้นตน้ (%) 39.9% 60.1% -20.2% 45.4% 61.1% -15.7%
EBITDA margin (%) 14.9% 22.2% -7.3% 16.7% 21.4% -4.7%
อตัรากาํไรสุทธิ (%) 10.5% 16.7% -6.2% 11.1% 15.8% -4.8%
สรุปผลประกอบการสาํคญัในไตรมาสที่ 3 ปี 2564 (งบการเงินรวม)
![Page 4: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/4.jpg)
Revenue from Sales
240.38
108.97
Q32021
Q32020
Revenue from Sales
121
615.18
306.75
9M2021
9M2020
101
Revenue from Sales
![Page 5: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/5.jpg)
97.13 100.65108.97
176.50
198.30
240.38
Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21
Revenue for Sales120.60% QoQ100.55% YoY
Unit : Million Baht
Revenue for Sales 9M/21
306.75
615.18
9M/20 9M/21
![Page 6: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/6.jpg)
Gross Profit
95.90
65.46
Q32021
Q32020
46
279.10
187.36
9M2021
9M2020
49
Gross Profit Gross Profit
![Page 7: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/7.jpg)
61.37 60.5365.46
86.46
96.74 95.90
1
Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21
Gross profit for 9M
Gross Profit
Gross profit for Q3
46.49% QoQ48.96% YoY
187.36
279.10
9M/20 9M/21
Unit : Million Baht
![Page 8: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/8.jpg)
65.46
95.90
Q3‐63 Q3‐64
187.36
279.10
9M‐63 9M‐64
Gross profit for 9M
Gross Profit
Gross profit for Q3
46.49% QoQ48.96% YoY
Unit : Million Baht
![Page 9: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/9.jpg)
Selling Expenses
36.27
28.22
Q32021
Q32020
29
83.85
9M2021
9M2020
43
Selling Expenses Selling Expenses
120.18
![Page 10: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/10.jpg)
Admin Expenses
28.68
13.43
Q22021
Q22020
39.13
9M2021
9M2020
Admin Expenses Admin Expenses
68.63
114
75
![Page 11: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/11.jpg)
Net Profit
26.41
20.41
Q32021
Q32020
29
72.14
53.75
9M2021
9M2020
34
Net Profit Net Profit
![Page 12: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/12.jpg)
Net Profit 39.30% QoQ
40.40% YoY
ส่วนทเีป็นของบร ิษัทใหญ่
13.87
16.93 18.46 18.68
24.76 25.71
Q1/20 Q2/20 Q3/20 Q1/21 Q2/21 Q3/21
49.25
69.15
9M/20 9M/21
Unit : Million Baht
![Page 13: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/13.jpg)
Net Profit
18.46
25.71
Q3‐63 Q3‐64
49.25
69.15
9M‐63 9M‐64
Unit : MB
39.30% QoQ
40.40% YoY
ส่วนทเีป็นของบร ิษัทใหญ่
Unit : Million Baht
![Page 14: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/14.jpg)
PHARMACEUTICAL INNOVATIONS
Note : 9M‐2021
22.54% 37.58% 1.25% 27.70% 10.93%
![Page 15: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/15.jpg)
Interpharma Group
A company specialized in research & development and distribution of animal’s healthcare products with paid-up registered capital of 5 million Baht
A research & business development company selling pet foodproducts with paid-up registered capital of 4 million Baht
A pharmaceutical company specialized in developing & producing pharmaceutical products for human and animals with paid-up registered capital of 295 million Baht
A research & business development JV company with Thai Union specialized in fish based nutraceuticals with registered capital of 2020 million Baht
55%
60%
100%
51%
100%
Teva Pharma (Thailand) Co., Ltd.Ayutthaya Factory
A pharmaceutical manufacturing plant combining of Silom Medical's diverse product portfolio and contracted manufacturing of Teva Pharma's generics portfolio
A leading nutraceutical company specialized in research & development and distribution of holistic healthcare products with paid-up registered capital of 103 million Baht
Confidential
![Page 16: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/16.jpg)
ORGANIZATION : Board of Director
16
Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director and
Chairman
Professor Dr.Sansanee ChaiyarojIndependent Director
Chairman of the Audit Committee
Mr.Kamtorn Sila-onIndependent Director
Chairman of the Audit Committee
Professor Piyamitr Sritara, MD, FRCP, FACP
Independent Director Chairman of the Audit Committee
Independent Directors
Dependent Directors
Trinnawat Thanitiphan Ph.D Miss Napaporn Dechakarat Miss Supaporn RerkpitakpanichDirector and Chief Executive Officer Director and Chief Operation Officer Director and Chief Financial Officer
Confidential
![Page 17: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/17.jpg)
ORGANIZATION : Board of Director
17
Clinical Professor Emeritus Udom Kachintorn, MD. Independent Director and
Chairman
Professor Dr.Sansanee ChaiyarojIndependent Director
Chairman of the Audit Committee
Mr.Kamtorn Sila-onIndependent Director
Audit Committee
Dr.Pao SriprasertsukIndependent Director
Audit Committee
Independent Directors
Dependent Directors
Trinnawat Thanitiphan Ph.D Miss Napaporn Dechakarat Miss Supaporn RerkpitakpanichDirector and Chief Executive Officer Director and Chief Operation Officer Director and Chief Financial Officer
Confidential
![Page 18: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/18.jpg)
2021 Company Highlights
![Page 19: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/19.jpg)
7 Growth Engines1. Current 5 business units : New Products /New Channels / New Markets
2. Modern Pharma CMO : Contract Manufacturing Service
3. Interpharma Ayuddhaya Site CMO : Teva
4. Bio Herbal Business : Hemp /CBD, Kratom Projects with Prince Songkhla University, other Thai Herbal Med
5. JV Business : Interpetrina (Asian), Interpharma-ZEAvita,
6. Medical Equipments with PJW
7. New Business Acquisitions : Retail / Wholesales
![Page 20: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/20.jpg)
Business Opportunities : Partnership & Collaboration
Confidential
JV : INTER PETRINA JV : INTERPHARMA ZEAVITA
![Page 21: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/21.jpg)
Business Opportunities : Partnership & Collaboration
Collaboration : 2 MOUs signing with Prince of Songkla University in collaboration to extend research & development on kratom and kratom
extractGovernment Funding : 45 million baht
Collaboration : MOU Signing with RBFon hemp/CBD extract project
Collaboration : MOU signing with PJW on Medical Device from recycled plastics
Confidential
![Page 22: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/22.jpg)
INTERPHARMA TEVA , Feb 9, 2021
![Page 23: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/23.jpg)
lnterpharma\' AL Ue YOUA L i f f ,Ayutthaya Site, Thailand
Area Type Area (Sq. M)Factory 4,932
Production Warehouse
3,5801,352
Utility building 500Maintenance area 100Office building 1,026Canteen 286Stability room 108Car park 1,650Green zone area 7,558Total Used area 16,160
Extendable area 17,280
Total Land Area 33,440
![Page 24: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/24.jpg)
Ayutthaya
Unit : Million Baht
11.07
16.04
‐
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
Q3‐64 Q4‐64F
Ayutthaya Pharmaceutical
10.45
29.97
‐
5.00
10.00
15.00
20.00
25.00
30.00
35.00
Q3‐64 Q4‐64F
OEM to Teva
![Page 25: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/25.jpg)
JANUARY 7, 2021
![Page 26: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/26.jpg)
![Page 27: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/27.jpg)
PRODUCT PROFILE : COLLAGEN
ใหม่ ซวีติา้ แอคทฟี คอลลาเจน พลสั …แบบซอง
แอคทฟี-ไดเปปไทด ์100%ดูดซมึไดม้ากกว่า 70 เท่า
![Page 28: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/28.jpg)
ใหม่…ซวีติา้ ทูน่าโบนแคลเซยีม พลสั
ผงกระดูกทูน่าธรรมชาต ิ100%เขม้ขน้ 17 เท่า ในเม็ดเล็ก กลนื
ง่าย
PRODUCT PROFILE : CALCIUM
![Page 29: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/29.jpg)
MEDICAL LINEMEDICAL LINE
![Page 30: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/30.jpg)
Modern Pharma : ContractManufacturing Products
Confidential
![Page 31: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/31.jpg)
Modern Pharma : ContractManufacturing Products
Confidential
![Page 32: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/32.jpg)
Modern Pharma : ContractManufacturing Products
Confidential
![Page 33: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/33.jpg)
Modern Pharma : ContractManufacturing Products
Confidential
![Page 34: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/34.jpg)
![Page 35: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/35.jpg)
INTERPHARMA X HUAWEI, FEB 16, 2021
![Page 36: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/36.jpg)
![Page 37: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/37.jpg)
INTERPHARMA Launch Probiota BLMAR 17, 2021
![Page 38: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/38.jpg)
• โปรไบโอตกิ - Bifidobacterium animalis ssp. lactis,
จลุนิทรยีท์อ้งถิน่ ทีม่ตี ัง้แตเ่ด็กแรกเกดิ
• พรไีบโอตกิ – อนิูลนิ (Inulin) อาหารของจลุนิทรยีท์อ้งถิน่
ชนิดดใีนลาํไส ้
“ 2 Power synergistic”
Bifidobacterium animalis ssp. Lactis
Min 5 x10 9 cfuInulin 900 mg
Probiota BL: โพรไบโอตา้ บีแอล
![Page 39: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/39.jpg)
![Page 40: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/40.jpg)
![Page 41: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/41.jpg)
การศึกษา TS6 สูตรผิว เร ืองการ “ฝ้า”
![Page 42: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/42.jpg)
ทาน TS6 สูตรผิว ฝ้าดขี ึนภายใน 3 เดอืน
ศกึษาในผูห้ญิงไทย
อาย ุ 30 – 50 ปีจาํนวน 57 คนทานTS6 วนัละ 1 ซองระยะเวลานาน 3 เดือน
![Page 43: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/43.jpg)
• คอลลาเจนสูตรพเิศษ
• 7 โปรไบโอตกิ + 2 พร ีไบโอตกิ• ละลายงา่ย ดดูซมึเข ้าสู่ร ่างกายได้ด ี
• ไม่มกีลินคาว
• รสราสเบอรร์ ี
![Page 44: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/44.jpg)
![Page 45: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/45.jpg)
![Page 46: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/46.jpg)
![Page 47: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/47.jpg)
![Page 48: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/48.jpg)
![Page 49: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/49.jpg)
![Page 50: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/50.jpg)
![Page 51: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/51.jpg)
![Page 52: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/52.jpg)
![Page 53: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/53.jpg)
Herbal Medicine Application, Jan 29, 2021
![Page 54: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/54.jpg)
HEMP Products
![Page 55: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/55.jpg)
บร ิษัท ดรัก แคร ์จาํกัด
![Page 56: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/56.jpg)
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
![Page 57: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/57.jpg)
![Page 58: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/58.jpg)
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
Vision
![Page 59: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/59.jpg)
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
Reliability - fully operate according to Law and
FDA regulations
Pharmacist on duty all day with full range of medicines to serve
Various Product Assortment
Professional service
Premium store image and design
Easy accessible channels(Visible store and Online platform)
VAT REFUND,ALIPAY and WeChat for tourists
Why LAB Pharmacy?
![Page 60: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/60.jpg)
Product Category
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
General&Chronic Disease
Dermo Cosmetics
Vitamin & Supplement
Personal Care Sport Nutrition
Products for TouristsOrganic & Natural Products
OTC & Medical Healthcare
Food Snack & Beverage
![Page 61: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/61.jpg)
LAB Pharmacy Store
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
![Page 62: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/62.jpg)
Online Communications
Drugcare Company LimitedProprietary & ConfidentialLive Healthy
![Page 63: Q3-2021 FINANCIAL PERFORMANCE](https://reader033.fdocuments.net/reader033/viewer/2022050108/626ca8e8e2063b46441e97e5/html5/thumbnails/63.jpg)
Online Channel